Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
GLP-1 Receptor Agonist Market Key Takeaways Eli Lilly and Company, Sanofi, Novo-Nordisk A/S, AstraZeneca, Pfizer, Inc., Amgen, Inc., Innovent Biologics, Inc., PegBio Co., Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH Increasing prevalence of chronic diseases such as diabetes and obesity Increasing R&D activities for developing novel therapeutics Formulation advancements of oral GLP-1 receptor agonists Adverse effects associated with few GLP-1 agonist drugs Product recalls by market players With the increasing prevalence of diabetes and obesity, GLP-1 receptor agonists have become popular due to their effectiveness in glycemic control and weight reduction, offering a dual benefit in managing type 2 diabetes mellitus (T2DM)
10.1007/s13300-015-0127-x 32
Otherwise, for consistent side effects, using professional healthcare services is beneficial
Weight Loss in a Digital App-Based Diabetes Prevention Program Powered by Artificial Intelligence
Success We're Proud Of Success We're Proud Of I've been on the program for 3 months and I am lighter in every way
US$ 22.81
US$ 24.25
US$ 29.22
US$ 22.70
